I-Mab (IMAB) said the Center for Drug Evaluation of China National Medical Products Administration has accepted the company's IND application to initiate a phase 2 trial for enoblituzumab in combination with pembrolizumab in patients with selected solid tumors. The phase 2 trial will evaluate the efficacy of the combination of enoblituzumab and pembrolizumab.

Create Account

Dark

chart

exchange

Check out our Level2View

I-Mab (IMAB) said the Center for Drug Evaluation of China National Medical Products Administration has accepted the company's IND application to initiate a phase 2 trial for enoblituzumab in combination with pembrolizumab in patients with selected solid tumors. The phase 2 trial will evaluate the efficacy of the combination of enoblituzumab and pembrolizumab.

RTTNews | Sep 28, 2021 08:54AM EDT

08:53 Tuesday, September 28, 2021 (RTTNews.com) - I-Mab (IMAB) said the Center for Drug Evaluation of China National Medical Products Administration has accepted the company's IND application to initiate a phase 2 trial for enoblituzumab in combination with pembrolizumab in patients with selected solid tumors. The phase 2 trial will evaluate the efficacy of the combination of enoblituzumab and pembrolizumab.

I-Mab has in-licensed the rights to develop and commercialize enoblituzumab in Greater China from MacroGenics (MGNX).

Joan Shen, CEO of I-Mab, said: "We will be leveraging the data from clinical trials conducted by MacroGenics to advance the clinical development of enoblituzumab for approval in Greater China."

Read the original article on RTTNews ( https://www.rttnews.com/3228762/i-mab-reports-acceptance-of-ind-application-in-china-for-phase-2-trial-with-enoblituzumab.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved